CR20210158A - Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso - Google Patents

Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso

Info

Publication number
CR20210158A
CR20210158A CR20210158A CR20210158A CR20210158A CR 20210158 A CR20210158 A CR 20210158A CR 20210158 A CR20210158 A CR 20210158A CR 20210158 A CR20210158 A CR 20210158A CR 20210158 A CR20210158 A CR 20210158A
Authority
CR
Costa Rica
Prior art keywords
vitamin
making
methods
dosage forms
pediatric dosage
Prior art date
Application number
CR20210158A
Other languages
English (en)
Inventor
Reem Elamein Elsiddig
Marta Golec
John Gerard O'brien
Praful Balavant Deshpande
Stephen James Quinlan
James Joseph Mcdonald
Ken O'shea
Original Assignee
Opko Ireland Global Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Ireland Global Holdings Ltd filed Critical Opko Ireland Global Holdings Ltd
Publication of CR20210158A publication Critical patent/CR20210158A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe formas de dosificación pediátricas y de liberación modificada de compuestos de vitamina D, y métodos de elaboración y uso de las mismas.
CR20210158A 2018-08-31 2019-08-30 Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso CR20210158A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862725940P 2018-08-31 2018-08-31
PCT/IB2019/057360 WO2020044314A1 (en) 2018-08-31 2019-08-30 Vitamin d pediatric dosage forms, methods of making and using

Publications (1)

Publication Number Publication Date
CR20210158A true CR20210158A (es) 2021-05-21

Family

ID=68165642

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210158A CR20210158A (es) 2018-08-31 2019-08-30 Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso

Country Status (21)

Country Link
US (3) US11000480B2 (es)
EP (1) EP3843706A1 (es)
JP (1) JP2021535155A (es)
KR (1) KR20210054539A (es)
CN (1) CN112912067A (es)
AU (4) AU2019329905B2 (es)
BR (1) BR112021003788A2 (es)
CA (1) CA3110020A1 (es)
CL (2) CL2021000493A1 (es)
CO (1) CO2021003805A2 (es)
CR (1) CR20210158A (es)
DE (1) DE202019005769U1 (es)
EA (1) EA202190633A1 (es)
EC (1) ECSP21021189A (es)
IL (1) IL280937A (es)
MX (1) MX2020011740A (es)
PE (1) PE20211489A1 (es)
PH (1) PH12021550413A1 (es)
SG (1) SG11202101905YA (es)
TW (1) TW202034905A (es)
WO (1) WO2020044314A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116033940A (zh) 2020-04-06 2023-04-28 艾尔金制药有限公司 激活内源性抗菌药物治疗sars-cov-2感染
JP2023526980A (ja) 2020-05-31 2023-06-26 エアジェン ファーマ リミテッド ハードカプセル剤形及びその使用
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN114176164A (zh) * 2021-12-17 2022-03-15 广东驱动力生物科技股份有限公司 反刍动物用水溶性抗应激助剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59155309A (ja) * 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンｄ↓３類組成物
CA2065603C (en) * 1991-04-09 2007-04-03 Hiroki Itoh Stabilized vitamin d preparation
JP3722832B2 (ja) * 1992-06-22 2005-11-30 ルーナー、コーポレーション 経口用１α−ヒドロキシプレビタミンＤ
US7632518B2 (en) * 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
EP3095447B1 (en) * 2006-02-03 2021-11-24 OPKO Renal, LLC Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
CN104523707B (zh) 2007-04-25 2022-08-26 欧普科Ip 控股Ii 有限公司 包含维生素d化合物和蜡质载体的口服控释组合物
CN101584683A (zh) * 2009-06-12 2009-11-25 沈阳药科大学 美托拉宗缓释胶囊及其制备方法
WO2012047098A1 (en) * 2010-10-04 2012-04-12 Dishman Pharmaceuticals And Chemicals Ltd. Encapsulated fat-soluble vitamin
US9907758B2 (en) * 2012-01-09 2018-03-06 Panjab University Department Of Biotechnology (Dbt) Process for preparing solid lipid sustained release nanoparticles for delivery of vitamins
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US20160008377A1 (en) * 2014-07-12 2016-01-14 Aphios Corporation Formulations and compositions of vitamin d analogs for treating and preventing cancer and other diseases
CR20170085A (es) * 2014-08-07 2017-04-25 Opko Ireland Global Holdings Ltd Terapia adjuntiva con 25-hidroxi vitamina d
CN108420797B (zh) * 2018-05-09 2022-05-03 南京海融制药有限公司 维生素d类似物制剂及其制备方法

Also Published As

Publication number Publication date
IL280937A (en) 2021-04-29
AU2019329905B2 (en) 2024-02-01
PH12021550413A1 (en) 2021-09-27
SG11202101905YA (en) 2021-03-30
EA202190633A1 (ru) 2021-07-12
AU2019329905A1 (en) 2021-03-18
EP3843706A1 (en) 2021-07-07
US20220000783A1 (en) 2022-01-06
KR20210054539A (ko) 2021-05-13
BR112021003788A2 (pt) 2021-06-08
PE20211489A1 (es) 2021-08-11
MX2020011740A (es) 2021-04-19
ECSP21021189A (es) 2021-04-29
WO2020044314A1 (en) 2020-03-05
AU2024202877A1 (en) 2024-05-23
US11000480B2 (en) 2021-05-11
AU2021107168A4 (en) 2021-12-09
AU2021107174A4 (en) 2021-12-09
DE202019005769U1 (de) 2022-01-13
CA3110020A1 (en) 2020-03-05
US20210401752A1 (en) 2021-12-30
TW202034905A (zh) 2020-10-01
JP2021535155A (ja) 2021-12-16
CL2023002539A1 (es) 2024-02-23
CO2021003805A2 (es) 2021-04-19
US20200338006A1 (en) 2020-10-29
CL2021000493A1 (es) 2021-07-23
CN112912067A (zh) 2021-06-04

Similar Documents

Publication Publication Date Title
CL2017003103A1 (es) Compuestos de heteroarilo para la inhibición de cinasa
NZ731789A (en) Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
EP3675859A4 (en) COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
CR20210158A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
MY192927A (en) Fused bicyclic compounds for the treatment of disease
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
AU2018348359A8 (en) Extended release pharmaceutical formulation and methods of treatment
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MX2017016346A (es) Metodos de tratamiento con taselisib.
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
MX2015013048A (es) Forma cristalina de un compuesto ansiolitico.
MX2019010640A (es) Formas cristalinas de acido obeticolico.
WO2018211324A8 (en) Prodrugs for the treatment of disease
WO2018211323A8 (en) Heterocyclic compounds for the treatment of disease
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.
WO2018231704A8 (en) 6-BROMONICOTINAMIDE AND METHODS OF PREPARATION
MX2018007326A (es) Composicion para reducir la frecuencia de miccion, metodo para elaborar y utilizar la misma.